Caroline Algrin1,2, Jean-Louis Golmard3, Mauricette Michallet4, Oumedaly Reman5, Anne Huynh6, Aurore Perrot7, Anne Sirvent8, Adriana Plesa9, Véronique Salaun10, Marie-Christine Béné11, Dominique Bories12, Olivier Tournilhac13, Hélène Merle-Béral14, Véronique Leblond1,2, Magali Le Garff-Tavernier14, Nathalie Dhedin1,15. 1. Hématologie, Groupe Hospitalier Pitié-Salpêtrière, Paris, France. 2. Sorbonne Universités, UPMC Univ Paris 06, GRC n°11, GRECHY, Paris, France. 3. Unité de Recherche Clinique, Groupe Hospitalier Pitié-Salpêtrière, Paris, France. 4. Hématologie, Centre Hospitalo-Universitaire (CHU) E. Herriot, Lyon, France. 5. Hématologie, CHU de Caen, Caen, France. 6. Hématologie, CHU de Toulouse, Toulouse, France. 7. Hématologie, CHU de Nancy, Nancy, France. 8. Hématologie, CHU de Nice, Nice, France. 9. Laboratoire d'Hématologie, CHU E. Herriot, Lyon, France. 10. Laboratoire d'Hématologie, CHU de Caen, Caen, France. 11. Laboratoire d'Immunologie, CHU de Nancy, Nancy, France. 12. Laboratoire d'Hématologie, CHU Henri Mondor, Créteil, France. 13. Hématologie, CHU de Clermont-Ferrand, Clermont-Ferrand, France. 14. Laboratoire d'Hématologie, Groupe Hospitalier Pitié-Salpêtrière, Paris, France. 15. Unité d'Hématologie Adolescents Jeunes Adultes, Hôpital Saint-Louis, Paris, France.
Abstract
OBJECTIVES: This study investigates whether achieving complete remission (CR) with undetectable minimal residual disease (MRD) after allogeneic stem cell transplantation (allo-SCT) for chronic lymphocytic leukemia (CLL) affects outcome. METHODS: We retrospectively studied 46 patients transplanted for CLL and evaluated for post-transplant MRD by flow cytometry. RESULTS: At transplant time, 43% of the patients were in CR, including one with undetectable MRD, 46% were in partial response, and 11% had refractory disease. After transplant, 61% of the patients achieved CR with undetectable MRD status. By multivariate analysis, reaching CR with undetectable MRD 12 months after transplant was the only factor associated with better progression-free survival (P = 0.02) and attaining undetectable MRD, independently of the time of negativity, was the only factor that correlated with better overall survival (P = 0.04). CONCLUSION: Thus, achieving undetectable MRD status after allo-SCT for CLL is a major goal to improve post-transplant outcome.
OBJECTIVES: This study investigates whether achieving complete remission (CR) with undetectable minimal residual disease (MRD) after allogeneic stem cell transplantation (allo-SCT) for chronic lymphocytic leukemia (CLL) affects outcome. METHODS: We retrospectively studied 46 patients transplanted for CLL and evaluated for post-transplant MRD by flow cytometry. RESULTS: At transplant time, 43% of the patients were in CR, including one with undetectable MRD, 46% were in partial response, and 11% had refractory disease. After transplant, 61% of the patients achieved CR with undetectable MRD status. By multivariate analysis, reaching CR with undetectable MRD 12 months after transplant was the only factor associated with better progression-free survival (P = 0.02) and attaining undetectable MRD, independently of the time of negativity, was the only factor that correlated with better overall survival (P = 0.04). CONCLUSION: Thus, achieving undetectable MRD status after allo-SCT for CLL is a major goal to improve post-transplant outcome.
Authors: Marco Ladetto; Sebastian Böttcher; Nicolaus Kröger; Michael A Pulsipher; Peter Bader Journal: Bone Marrow Transplant Date: 2018-08-16 Impact factor: 5.483
Authors: Shenmiao Yang; Neil E Kay; Min Shi; Gert Ossenkoppele; Roland B Walter; Robert Peter Gale Journal: Leukemia Date: 2021-09-27 Impact factor: 11.528